FDA After the Storm: Drug Review Delays and Increased Executive Oversight Expected - BioSpace
After the gutting of the Department of Health and Human Services, fears mount about the future direction of the FDA—with regulatory experts predicting delays in drug approvals and greater influence of political appointees.| BioSpace
